描述

Viscosupplementation is the term that describes the use of intraarticular hyaluronates for the treatment of pain in osteoarthritic joints. Viscosupplementation is a highly used palliative treatment for knee OA because of ease of application and theoretical ability to relieve symptoms by restoring and replenishing hyaluronate component into the knee joint. The global viscosupplementation market in terms of revenue is set to grow by US$ 2 亿期间 2021-2027, 以复合年增长率增长 (复合年增长率) 的 8.7% 在预测期内, 据数据和分析公司 StrategyHelix 称. Growth in the geriatric population, increasing prevalence of knee osteoarthritis, rapid expansion of healthcare facilities in developing economies are expected to boost the market growth in the coming years.

该报告提供了该时期的最新市场规模数据 2017-2020 并预测到 2027 covering key market aspects like sales value for viscosupplementation. The global viscosupplementation market is segmented on the basis of product, 应用, 地区. 副产品, it is categorized into single-injection cycle, three-injection cycle, and five-injection cycle. The three-injection cycle segment held the largest market share in 2020. 按申请, the viscosupplementation market is divided into knee osteoarthritis, hip osteoarthritis, shoulder osteoarthritis, 和别的. The knee osteoarthritis segment accounted for the largest market share in 2020. Based on region, the viscosupplementation market is divided into North America, 亚太地区, 欧洲, 和世界其他地区 (排).

The report has profiled some of the key players of the market such as Altergon Italia Srl, Anika Therapeutics Inc., Bioventus LLC, Bloomage Freda Biopharm Co. 有限公司, Chugai Pharmaceutical Co. 有限公司, Contipro a.s., Ferring Pharmaceuticals AS, Fidia Farmaceutici S.p.A., 丘比公司, Lifecore Biomedical Inc., 明治控股公司. 有限公司, 赛诺菲公司, Seikagaku Corporation, Zimmer Biomet Holdings Inc..

该报告对于活跃在该行业的公司和组织来说是宝贵的资源. It provides a cohesive picture of the viscosupplementation market to help drive informed decision making for industry executives, 政策制定者, 学术的, 和分析师.

报告范围

产品: single-injection cycle, three-injection cycle, and five-injection cycle
应用: knee osteoarthritis, hip osteoarthritis, shoulder osteoarthritis, 和别的
地区: 北美, 亚太地区, 欧洲, 和世界其他地区 (排)
考虑年数: 本报告涵盖期间 2017 到 2027

利益相关者的主要好处

Get a comprehensive picture of the global viscosupplementation market
精准定位增长领域和投资趋势
Understand what the future of the global viscosupplementation market looks like
确定竞争格局和机会之窗

目录

1. 市场定义
2. 研究方法论
3. 市场数据 & 外表
3.1 市场价值
3.2 市场价值预测
4. Viscosupplementation Market by Product
4.1 Single-Injection Cycle
4.2 Three-Injection Cycle
4.3 Five-Injection Cycle
5. Viscosupplementation Market by Application
5.1 Knee Osteoarthritis
5.2 Hip Osteoarthritis
5.3 Shoulder Osteoarthritis
5.4 其他的
6. Viscosupplementation Market by Region
6.1 北美
6.2 亚太地区
6.3 欧洲
6.4 世界其他地区 (排)
7. 公司简介
7.1 Altergon Italia Srl
7.2 Anika Therapeutics Inc.
7.3 Bioventus LLC
7.4 Bloomage Freda Biopharm Co., 有限公司.
7.5 Chugai Pharmaceutical Co. 有限公司.
7.6 Contipro a.s.
7.7 Ferring Pharmaceuticals AS
7.8 Fidia Farmaceutici S.p.A.
7.9 丘比公司
7.10 Lifecore Biomedical, 公司.
7.11 明治控股公司, 有限公司.
7.12 赛诺菲公司.
7.13 Seikagaku Corporation
7.14 Zimmer Biomet Holdings, 公司.
8. 附录
8.1 关于StrategyHelix
8.2 免责声明